5-Amino-1MQ: Research Overview

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule compound that has attracted growing attention in metabolic research. As a selective inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase), it represents a novel approach to studying fat cell metabolism and energy expenditure at the cellular level. This overview covers what researchers need to know about 5-Amino-1MQ, its mechanism of action, and the current state of the preclinical data.

What Is 5-Amino-1MQ?

5-Amino-1MQ is a cell-permeable, small molecule inhibitor developed specifically to target NNMT activity. It was developed by researchers studying the role of NNMT in adipose tissue biology and metabolic dysfunction. As a small molecule, it is far smaller than most peptide research compounds — see the Research Identity table below for verified molecular data — making it small enough to readily enter cells, a key advantage for a compound targeting an intracellular enzyme.

Unlike many research peptides which are derived from biological sources, 5-Amino-1MQ is a synthetic small molecule. This distinction is relevant to researchers because it affects stability, storage, and reconstitution requirements compared to peptide-based compounds.

5-Amino-1MQ Research Identity

* 5-Amino-1MQ is a quaternary ammonium cation and requires a counterion (typically chloride or iodide) to exist as an isolable solid, so the true molecular weight of the supplied material depends on the salt form: chloride salt ≈194.7 g/mol, iodide salt ≈286.1 g/mol, independently computed from each formula. Supplier and database listings for this compound are inconsistent — one major chemical database lists the chloride CAS number with the iodide salt’s molecular formula and weight attached. Confirm the exact salt form and molecular weight against your supplier’s own COA rather than relying on any single third-party listing, including this one.

NNMT: The Target Enzyme

To understand 5-Amino-1MQ, researchers need to understand its target. NNMT (nicotinamide N-methyltransferase) is an enzyme that catalyzes the methylation of nicotinamide — a form of vitamin B3 — using S-adenosyl methionine (SAM) as the methyl donor. This reaction produces 1-methylnicotinamide (1-MNA) and S-adenosyl homocysteine (SAH).

NNMT is highly expressed in adipose (fat) tissue and liver. Research has shown that NNMT activity is elevated in obese and diabetic states in both animal models and human tissue samples. High NNMT activity consumes SAM and reduces the availability of methyl groups for other cellular processes, including the methylation reactions involved in regulating gene expression and metabolism.

By consuming SAM, active NNMT also indirectly reduces NAD+ precursor availability — creating a link between NNMT activity and the cellular NAD+/sirtuin axis that has become central to metabolic aging research.

Mechanism of Action

5-Amino-1MQ works by competitively inhibiting NNMT. When NNMT is inhibited, several downstream effects have been observed in preclinical models:

SAM Conservation

By blocking NNMT, cellular SAM levels are preserved. This supports methylation reactions throughout the cell, including histone methylation and DNA methylation patterns that regulate gene expression in metabolically important pathways.

NAD+ Precursor Availability

Inhibiting NNMT reduces the consumption of nicotinamide, potentially increasing its availability for conversion to NAD+ via the salvage pathway. This mechanism connects 5-Amino-1MQ research to the broader NAD+ biology field.

Adipocyte Effects

In fat cells specifically, NNMT inhibition has been associated in animal studies with reduced lipid accumulation, increased energy expenditure markers, and changes in the expression of genes involved in lipolysis and thermogenesis. These observations have made 5-Amino-1MQ a compound of interest in obesity and metabolic syndrome research.

Key Preclinical Findings

The foundational research on 5-Amino-1MQ was largely developed through work published by researchers at Rutgers University and collaborating institutions. Key observations from animal studies include:

• Diet-induced obesity models: Mice given 5-Amino-1MQ under high-fat diet conditions showed reduced weight gain and improved metabolic markers compared to controls, without significant changes in food intake — suggesting effects on energy expenditure rather than appetite suppression.
• Adipose tissue gene expression: Studies noted changes in expression of genes related to fat oxidation and thermogenesis in animals given the compound.
• NAD+ and sirtuin pathway effects: Consistent with the proposed mechanism, NNMT inhibition was associated with changes in NAD+ levels and sirtuin activity markers in adipose tissue.
• Absence of hepatotoxicity signals: In available animal studies, 5-Amino-1MQ did not produce significant liver toxicity signals at the concentrations studied, which is a relevant safety consideration for an enzyme expressed in liver tissue.

It is important to note that all of this data comes from in vitro cell studies and rodent models. No human clinical trials of 5-Amino-1MQ have been published to date, and the compound has not been evaluated by the FDA or any regulatory body for human medical use.

Comparison to Related Approaches

5-Amino-1MQ is sometimes discussed alongside other metabolic research compounds. Its unique position as an NNMT inhibitor distinguishes it from:

• NAD+ precursors (NMN, NR): These work by supplying raw material for NAD+ synthesis. 5-Amino-1MQ works upstream by reducing NAD+ precursor consumption.
• Sirtuin activators: Compounds like resveratrol target sirtuins directly. 5-Amino-1MQ affects sirtuin activity indirectly through NAD+ availability.
• Metabolic peptides: Unlike peptides such as Tesamorelin or AOD-9604, 5-Amino-1MQ operates through a completely different molecular mechanism focused on methylation biology.

Storage and Handling

5-Amino-1MQ is typically supplied as a powder. For research use, it should be stored at -20°C in a dry, dark environment. It can be reconstituted in DMSO for stock solutions, with further dilution in aqueous buffers for cell culture applications. Researchers should prepare working solutions fresh where possible and avoid repeated freeze-thaw cycles.

Sourcing Considerations

As interest in 5-Amino-1MQ has grown, so has the number of suppliers offering the compound. Quality varies significantly. Researchers should prioritize suppliers who provide independent third-party mass spectrometry data confirming molecular identity, HPLC purity data (ideally 99%+), and batch-specific COA documentation. Given the specificity of this compound’s mechanism, impurities or incorrect synthesis can significantly confound research results.

Conclusion

5-Amino-1MQ represents a novel and mechanistically distinct approach to metabolic research. As an NNMT inhibitor, it operates at an intersection of methylation biology, NAD+ metabolism, and adipose tissue function that is increasingly recognized as central to metabolic health and aging. While the preclinical data is promising, the field is still in early stages and human data is absent. Researchers working in metabolic biology, obesity, or longevity science will find 5-Amino-1MQ a compelling compound to investigate.

AminoForge supplies 5-Amino-1MQ for research and laboratory use with independent third-party testing and COA documentation on every batch.

Shop 5-Amino-1MQ at AminoForge

Neelakantan et al.: Selective and membrane-permeable small molecule NNMT inhibitors reverse high-fat diet-induced obesity in mice (PubMed)

Note: All compounds sold by AminoForge are intended for research use only. They are not intended for human consumption, and no claims are made regarding medical or health applications.